About Character Biosciences

Character is a precision medicine company focused on macular degeneration and primary open-angle glaucoma, utilizing clinical genomic databases and machine learning to identify genetic drivers of disease progression. By characterizing patient subtypes, Character aims to develop targeted therapies for conditions that currently have limited treatment options.

```xml <problem> Age-related macular degeneration (AMD) and primary open-angle glaucoma (POAG) are progressive polygenic diseases that are currently treated as homogeneous conditions, despite diverse patient subtypes and disease progression patterns. This lack of granularity limits the effectiveness of existing treatments. </problem> <solution> Character is a precision medicine company focused on identifying the genetic drivers of disease progression in AMD and POAG. The company builds clinical genomic databases and applies machine learning to characterize patient subtypes, enabling the discovery and development of targeted therapies. By integrating genomics with longitudinal clinical data, ophthalmic imaging, and AI/ML-powered quantification of disease progression phenotypes, Character aims to increase the probability of success for translating discoveries into medicines. The company's platform facilitates drug target selection, clinical endpoint prioritization, patient stratification, and accelerated clinical trial execution. </solution> <features> - World-class clinical genomic databases in AMD and POAG to characterize the diversity of patient subtypes. - Integration of genomics with longitudinal clinical data, ophthalmic imaging, and AI/ML-powered quantification of disease progression phenotypes. - Identification of drug targets and pathways associated with disease progression. - Development and evaluation of multimodal patient biomarkers for patient stratification. - AI/ML powered quantification of disease progression phenotypes and clinical endpoints. </features> <target_audience> The primary target audience includes patients, ophthalmologists, treating physicians, and industry partners interested in advancing precision medicine for ophthalmic diseases like AMD and POAG. </target_audience> ```

What does Character Biosciences do?

Where is Character Biosciences located?

Character Biosciences is based in Jersey City, United States.

When was Character Biosciences founded?

Character Biosciences was founded in 2018.

How much funding has Character Biosciences raised?

Character Biosciences has raised 23950000.

Location

Jersey City, United States

Founded

2018

Funding

23950000

Employees

36 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Character Biosciences

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

characterbio.com 3K+

Founded 2018 – Jersey City, United States

Funding

Estimated Funding

$20M+

Team (30+)

No team information available.

Company Description

Problem

Age-related macular degeneration (AMD) and primary open-angle glaucoma (POAG) are progressive polygenic diseases that are currently treated as homogeneous conditions, despite diverse patient subtypes and disease progression patterns. This lack of granularity limits the effectiveness of existing treatments.

Solution

Character is a precision medicine company focused on identifying the genetic drivers of disease progression in AMD and POAG. The company builds clinical genomic databases and applies machine learning to characterize patient subtypes, enabling the discovery and development of targeted therapies. By integrating genomics with longitudinal clinical data, ophthalmic imaging, and AI/ML-powered quantification of disease progression phenotypes, Character aims to increase the probability of success for translating discoveries into medicines. The company's platform facilitates drug target selection, clinical endpoint prioritization, patient stratification, and accelerated clinical trial execution.

Features

World-class clinical genomic databases in AMD and POAG to characterize the diversity of patient subtypes.

Integration of genomics with longitudinal clinical data, ophthalmic imaging, and AI/ML-powered quantification of disease progression phenotypes.

Identification of drug targets and pathways associated with disease progression.

Development and evaluation of multimodal patient biomarkers for patient stratification.

AI/ML powered quantification of disease progression phenotypes and clinical endpoints.

Target Audience

The primary target audience includes patients, ophthalmologists, treating physicians, and industry partners interested in advancing precision medicine for ophthalmic diseases like AMD and POAG.